Good Samarium.

The phase 2 RTOG 0622 evaluated Samarium-153 (2.0 mCi/kg intravenously × 1) followed by salvage external beam radiation in men with post-prostatectomy biochemically recurrent prostate cancer. While tolerated well, the primary endpoint of PSA response rate at 12 weeks (13.5%) was almost half of that hypothesized (25%). You gave it a good go, Samarium, but you were fighting a losing battle on patients without ADT, or known cancer in the bone, on board.